Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Syndax Pharmaceuticals Q3 EPS $(0.70) Beats $(0.73) Estimate, Sales $45.871M Miss $47.976M Estimate

Author: Benzinga Newsdesk | November 03, 2025 04:03pm
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.73) by 3.98 percent. This is a 28.57 percent increase over losses of $(0.98) per share from the same period last year. The company reported quarterly sales of $45.871 million which missed the analyst consensus estimate of $47.976 million by 4.39 percent. This is a 266.97 percent increase over sales of $12.500 million the same period last year.

Posted In: SNDX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist